Susquehanna International Group, LLP Pliant Therapeutics, Inc. Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$10.52 - $14.35 $567,028 - $773,465	53,900 Added 330.67%	70,200 $786,000
Q2 2024 Aug 15, 2024	SELL	$10.58 - $15.61 $226,412 - $334,054	-21,400 Reduced 56.76%	16,300 $175,000
Q1 2024 May 07, 2024	BUY	$14.14 - $19.59 $227,654 - $315,399	16,100 Added 74.54%	37,700 $561,000
Q4 2023 Feb 14, 2024	SELL	$12.85 - $19.15 $584,675 - $871,324	-45,500 Reduced 67.81%	21,600 $391,000
Q3 2023 Nov 14, 2023	BUY	$14.58 - $20.15 $242,028 - $334,490	16,600 Added 32.87%	67,100 $1.16 Million
Q2 2023 Aug 11, 2023	SELL	$18.12 - $30.56 $956,736 - $1.61 Million	-52,800 Reduced 51.11%	50,500 $915,000
Q1 2023 May 16, 2023	BUY	$18.73 - $36.26 $580,630 - $1.12 Million	31,000 Added 42.88%	103,300 $2.75 Million
Q4 2022 Feb 14, 2023	BUY	$17.0 - $25.43 $370,600 - $554,374	21,800 Added 43.17%	72,300 $1.4 Million
Q3 2022 Nov 14, 2022	SELL	$7.67 - $24.23 $234,702 - $741,438	-30,600 Reduced 37.73%	50,500 $1.06 Million

168

63.2M

245K

373K

Ticker PLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,682,000
Market Cap $647M
Description
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.